Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy BioSpaceIn November 2025, one patient died after receiving Intellia Therapeutics' investigational gene silencer for transthyretin amyloidosis.Rare DiseaseRead full story pharminent August 7, 2026 (Last updated: August 8, 2026) BioSpace In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatmentsNext: Replimune Readies Launch of Newly Approved Melanoma Therapy Tudriqev Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
